Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Study of the Efficacy and Safety of Ranibizumab Injection in Patients With Macular Edema Secondary to Branch Retinal Vein Occlusion (BRAVO)

This study has been completed.
Sponsor:
Information provided by:
Genentech, Inc.
ClinicalTrials.gov Identifier:
NCT00486018
First received: June 11, 2007
Last updated: April 25, 2011
Last verified: April 2011
Results First Received: August 16, 2010  
Study Type: Interventional
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: Double Blind (Subject, Investigator);   Primary Purpose: Treatment
Conditions: Macular Edema
Retinal Vein Occlusion
Interventions: Drug: Ranibizumab injection 0.3 mg
Drug: Ranibizumab injection 0.5 mg
Drug: Sham injection

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Please note that although the table below is titled "Overall Study," the completion rates are for the 6-month Treatment Period only (i.e., does not include the 6-month Observation Period data).

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Sham Injection Sham injection in a single-dose regimen given every month (Day 0 through the Month 5 visit), for a total of six sham injections.
Ranibizumab Injection 0.3 mg Ranibizumab injection 0.3 mg in a single-dose regimen given every month (Day 0 through the Month 5 visit), for a total of six injections.
Ranibizumab Injection 0.5 mg Ranibizumab injection 0.5 mg in a single-dose regimen given every month (Day 0 through the Month 5 visit), for a total of six injections.

Participant Flow:   Overall Study
    Sham Injection     Ranibizumab Injection 0.3 mg     Ranibizumab Injection 0.5 mg  
STARTED     132     134     131  
Received Drug (Safety Population)     131     134     130  
COMPLETED     123     128     125  
NOT COMPLETED     9     6     6  



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Sham Injection Sham injection in a single-dose regimen given every month (Day 0 through the Month 5 visit), for a total of six sham injections.
Ranibizumab Injection 0.3 mg Ranibizumab injection 0.3 mg in a single-dose regimen given every month (Day 0 through the Month 5 visit), for a total of six injections.
Ranibizumab Injection 0.5 mg Ranibizumab injection 0.5 mg in a single-dose regimen given every month (Day 0 through the Month 5 visit), for a total of six injections.
Total Total of all reporting groups

Baseline Measures
    Sham Injection     Ranibizumab Injection 0.3 mg     Ranibizumab Injection 0.5 mg     Total  
Number of Participants  
[units: participants]
  132     134     131     397  
Age  
[units: years]
Mean ± Standard Deviation
  65.2  ± 12.7     66.6  ± 11.2     67.5  ± 11.8     66.4  ± 11.9  
Age, Customized  
[units: participants]
       
< 45 years     8     5     4     17  
45 to < 65 years     59     51     51     161  
65 to < 85 years     60     74     69     203  
≥ 85 years     5     4     7     16  
Gender  
[units: participants]
       
Female     58     67     60     185  
Male     74     67     71     212  



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Mean Change From Baseline in Best Corrected Visual Acuity (BCVA) Score at 6 Months   [ Time Frame: Baseline and 6 months ]

2.  Secondary:   Percentage of Participants Who Gained ≥ 15 Letters in BCVA Score at Month 6 Compared With Baseline   [ Time Frame: Baseline and 6 months ]

3.  Secondary:   Percentage of Participants Who Lost < 15 Letters in BCVA Score at Month 6 Compared With Baseline   [ Time Frame: Baseline and 6 months ]

4.  Secondary:   Percentage of Participants With a Central Foveal Thickness of ≤ 250 μm at Month 6   [ Time Frame: 6 months ]

5.  Secondary:   Mean Absolute Change From Baseline in Central Foveal Thickness at Month 6   [ Time Frame: Baseline and 6 months ]

6.  Secondary:   Mean Change From Baseline in the National Eye Institute Visual Functioning Questionnaire-25 (NEI VFQ-25) Near Activities Subscale Score at Month 6   [ Time Frame: Baseline and 6 months ]

7.  Secondary:   Mean Change From Baseline in the NEI VFQ-25 Distance Activities Subscale Score at Month 6   [ Time Frame: Baseline and 6 months ]


  Serious Adverse Events
  Hide Serious Adverse Events

Time Frame 6 months
Additional Description Investigators assessed the occurrence of AE/SAEs at all study visits. Summaries are for the safety-evaluable population and include events regardless of relation to study drug or location (e.g. non-study eye events are included). For each AE/SAE, the number of patients experiencing the event, not the number of occurrences of the event, is reported.

Reporting Groups
  Description
Sham Injection Sham injection in a single-dose regimen given every month (Day 0 through the Month 5 visit), for a total of six sham injections.
Ranibizumab Injection 0.3 mg Ranibizumab injection 0.3 mg in a single-dose regimen given every month (Day 0 through the Month 5 visit), for a total of six injections.
Ranibizumab Injection 0.5 mg Ranibizumab injection 0.5 mg in a single-dose regimen given every month (Day 0 through the Month 5 visit), for a total of six injections.

Serious Adverse Events
    Sham Injection     Ranibizumab Injection 0.3 mg     Ranibizumab Injection 0.5 mg  
Total, serious adverse events        
# participants affected / at risk     6/131 (4.58%)     14/134 (10.45%)     14/130 (10.77%)  
Cardiac disorders        
Acute Myocardial Infarction † 1      
# participants affected / at risk     0/131 (0.00%)     0/134 (0.00%)     1/130 (0.77%)  
Angina Unstable † 1      
# participants affected / at risk     0/131 (0.00%)     0/134 (0.00%)     1/130 (0.77%)  
Bradycardia † 1      
# participants affected / at risk     0/131 (0.00%)     0/134 (0.00%)     1/130 (0.77%)  
Ear and labyrinth disorders        
Vertigo † 1      
# participants affected / at risk     0/131 (0.00%)     1/134 (0.75%)     0/130 (0.00%)  
Eye disorders        
Glaucoma † 1      
# participants affected / at risk     0/131 (0.00%)     1/134 (0.75%)     0/130 (0.00%)  
Gaze Palsy † 1      
# participants affected / at risk     0/131 (0.00%)     0/134 (0.00%)     1/130 (0.77%)  
Visual Acuity Reduced † 1      
# participants affected / at risk     0/131 (0.00%)     1/134 (0.75%)     0/130 (0.00%)  
Retinal Ischemia † 1      
# participants affected / at risk     0/131 (0.00%)     1/134 (0.75%)     0/130 (0.00%)  
Retinal Neovascularization † 1      
# participants affected / at risk     1/131 (0.76%)     0/134 (0.00%)     0/130 (0.00%)  
Retinal Vein Occlusion † 1      
# participants affected / at risk     0/131 (0.00%)     0/134 (0.00%)     1/130 (0.77%)  
Retinal Detachment † 1      
# participants affected / at risk     0/131 (0.00%)     1/134 (0.75%)     0/130 (0.00%)  
Retinal Tear † 1      
# participants affected / at risk     0/131 (0.00%)     1/134 (0.75%)     0/130 (0.00%)  
Macular Edema † 1      
# participants affected / at risk     1/131 (0.76%)     0/134 (0.00%)     0/130 (0.00%)  
Gastrointestinal disorders        
Colonic Polyp † 1      
# participants affected / at risk     0/131 (0.00%)     0/134 (0.00%)     1/130 (0.77%)  
Small Intestinal Obstruction † 1      
# participants affected / at risk     0/131 (0.00%)     1/134 (0.75%)     1/130 (0.77%)  
Intra-Abdominal Hematoma † 1      
# participants affected / at risk     0/131 (0.00%)     1/134 (0.75%)     0/130 (0.00%)  
Rectal Hemorrhage † 1      
# participants affected / at risk     0/131 (0.00%)     1/134 (0.75%)     0/130 (0.00%)  
Intestinal Perforation † 1      
# participants affected / at risk     0/131 (0.00%)     0/134 (0.00%)     1/130 (0.77%)  
Hepatobiliary disorders        
Cholecystitis † 1      
# participants affected / at risk     0/131 (0.00%)     1/134 (0.75%)     0/130 (0.00%)  
Infections and infestations        
Cellulitis † 1      
# participants affected / at risk     0/131 (0.00%)     0/134 (0.00%)     1/130 (0.77%)  
Osteomyelitis † 1      
# participants affected / at risk     0/131 (0.00%)     1/134 (0.75%)     0/130 (0.00%)  
Endophthalmitis † 1      
# participants affected / at risk     0/131 (0.00%)     0/134 (0.00%)     1/130 (0.77%)  
Lobar Pneumonia † 1      
# participants affected / at risk     0/131 (0.00%)     1/134 (0.75%)     0/130 (0.00%)  
Pneumonia † 1      
# participants affected / at risk     1/131 (0.76%)     2/134 (1.49%)     0/130 (0.00%)  
Sinusitis † 1      
# participants affected / at risk     0/131 (0.00%)     1/134 (0.75%)     0/130 (0.00%)  
Urinary Tract Infection † 1      
# participants affected / at risk     1/131 (0.76%)     0/134 (0.00%)     0/130 (0.00%)  
Gastroenteritis Viral † 1      
# participants affected / at risk     0/131 (0.00%)     1/134 (0.75%)     0/130 (0.00%)  
Injury, poisoning and procedural complications        
Corneal Abrasion † 1      
# participants affected / at risk     0/131 (0.00%)     1/134 (0.75%)     0/130 (0.00%)  
Post Procedural Hemorrhage † 1      
# participants affected / at risk     0/131 (0.00%)     0/134 (0.00%)     1/130 (0.77%)  
Pelvic Fracture † 1      
# participants affected / at risk     1/131 (0.76%)     0/134 (0.00%)     0/130 (0.00%)  
Metabolism and nutrition disorders        
Diabetes Mellitus † 1      
# participants affected / at risk     0/131 (0.00%)     0/134 (0.00%)     1/130 (0.77%)  
Dehydration † 1      
# participants affected / at risk     0/131 (0.00%)     0/134 (0.00%)     1/130 (0.77%)  
Musculoskeletal and connective tissue disorders        
Arthritis † 1      
# participants affected / at risk     0/131 (0.00%)     1/134 (0.75%)     0/130 (0.00%)  
Neoplasms benign, malignant and unspecified (incl cysts and polyps)        
Gastric Cancer † 1      
# participants affected / at risk     0/131 (0.00%)     0/134 (0.00%)     1/130 (0.77%)  
Nervous system disorders        
Cerebral Hemorrhage † 1      
# participants affected / at risk     0/131 (0.00%)     0/134 (0.00%)     1/130 (0.77%)  
Thalamus Hemorrhage † 1      
# participants affected / at risk     1/131 (0.76%)     0/134 (0.00%)     0/130 (0.00%)  
Respiratory, thoracic and mediastinal disorders        
Chronic Obstructive Pulmonary Disease † 1      
# participants affected / at risk     1/131 (0.76%)     0/134 (0.00%)     0/130 (0.00%)  
Pleural Effusion † 1      
# participants affected / at risk     0/131 (0.00%)     0/134 (0.00%)     1/130 (0.77%)  
Vascular disorders        
Hypertension † 1      
# participants affected / at risk     0/131 (0.00%)     2/134 (1.49%)     0/130 (0.00%)  
Events were collected by systematic assessment
1 Term from vocabulary, MedDRA (12.0)




  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information